Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Dec:26 Suppl 1:81-88.
doi: 10.1111/1744-9987.13780. Epub 2022 Dec 5.

The German Lipoprotein Apheresis Registry-Summary of the ninth annual report

Volker J J Schettler  1 , Christian Peter  2 , Thomas Zimmermann  3 , Ulrich Julius  4 , Eberhard Roeseler  5 , Georg Schlieper  5 , Franz Heigl  6 , Peter Grützmacher  7 , Iris Löhlein  8 , Reinhard Klingel  9 , Bernd Hohenstein  10 , Wolfgang Ramlow  11 , Anja Vogt  12 ; Scientific Board of GLAR for the German Apheresis Working Group
Affiliations
Observational Study

The German Lipoprotein Apheresis Registry-Summary of the ninth annual report

Volker J J Schettler et al. Ther Apher Dial. 2022 Dec.

Abstract

During 2012-2020, 89 German apheresis centers collected retrospective and prospective observational data of 2028 patients undergoing regular lipoprotein apheresis (LA) for the German Lipoprotein Apheresis Registry (GLAR). More than 47 500 LA sessions are documented in GLAR. In 2020, all patients treated with LA showed a high immediate median reduction rate of LDL-C (68.2%, n = 1055) and Lp(a) (72.4%, n = 994). Patient data were analyzed for the incidence rate of major coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y-1) and prospectively up to 7 years on LA (y + 1 to y + 7). During the first 2 years of LA (y + 1 and y + 2), a MACE reduction of 78% was observed. Current analysis of GLAR data shows very low incidence rates of cardiovascular events in patients with high LDL-C and/or high Lp(a) levels, progressive ASCVD, and maximally tolerated lipid lowering medication regular by LA results.

PubMed Disclaimer

References

REFERENCES

    1. Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287:2-18. https://doi.org/10.1111/joim.12981
    1. Katzmann JL, Packard CJ, Chapman MJ, Katzmann I, Laufs U. Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:563-79. https://doi.org/10.1016/j.jacc.2020.05.070
    1. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22. https://doi.org/10.1056/NEJMoa1615664
    1. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-107. https://doi.org/10.1056/NEJMoa1801174
    1. van Bruggen FH, Nijhuis GBJ, Zuidema SU, Luijendijk H. Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review. Expert Rev Clin Pharmacol. 2020;13:787-96. https://doi.org/10.1080/17512433.2020.1787832

Publication types

LinkOut - more resources